Evaluation of differences in reaction times according to drugs in relapsing-remitting multiple sclerosis patients

Authors

  • Karen Aracelly Tobar Almendariz
  • Olga Cristina Solis Solis
  • Icler Sisalema Aguilar

Keywords:

Multiple Sclerosis, neurological disease, reaction times, Friedman test, sphericity test

Abstract

Introduction: Multiple Sclerosis is a neurological disease that affects cognitive and motor function.

Objective: The objective of the study was to demonstrate differences in reaction times to three different drugs in patients with relapsing-remitting multiple sclerosis at the Hospital in Ecuador. 

Methods: It was a prospective, experimental and analytical study developed with 12 patients with relapsing-remitting multiple sclerosis, from the hospital under study. The Friedman test was used with the support of SPSS statistical software.

Results: It was observed that, in general, reaction times varied among these drugs, suggesting that the choice of drug may influence patients' reaction speed. Pairwise comparisons of reaction times revealed significant differences in times. Mauchly's test of sphericity indicated that the error covariance matrix of variables conformed to the assumption of sphericity, which supported the validity of the analysis of reaction time effects in this study. Significant mean differences were observed in some pairwise comparisons.

Conclusions: Statistical analyses revealed that the study hypothesis was met as statistically significant variations were found in reaction times in response to the three drugs: Avonex, Gilenya and Tysabri. These results supported the original hypothesis which posited the presence of notable differences in reaction time in relation to the drugs evaluated.

Downloads

Download data is not yet available.

Published

2023-11-10

How to Cite

1.
Tobar Almendariz KA, Solis Solis OC, Sisalema Aguilar I. Evaluation of differences in reaction times according to drugs in relapsing-remitting multiple sclerosis patients. Rev Cubana Inv Bioméd [Internet]. 2023 Nov. 10 [cited 2025 Jul. 12];42(2). Available from: https://revibiomedica.sld.cu/index.php/ibi/article/view/3068